PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpbsHomeCurrent issueInstructionsSubmit article
 
J Pharm Bioallied Sci. 2010 Oct-Dec; 2(4): 372–375.
PMCID: PMC2996073

Spectrophotometric method for simultaneous estimation of atenolol in combination with losartan potassium and hydrochlorothiazide in bulk and tablet formulation

Abstract

Aim:

To develop a simple, accurate, rapid and precise UV spectrophotometric method for the estimation of atenolol in combination with losartan potassium and hydrochlorothiazide.

Materials and Methods:

The method employs formation and solving simultaneous equation using 251.60 nm and 224.20 nm for losartan potassium and atenolol, 224.20 and 271.60 for atenolol and hydrochlorothiazide as two analytical wavelengths, using methanol water as a solvent.

Results and Conclusion:

The linearity was observed in the concentration range of 5-30 µg/ml (r=0.9991) for losratan pottassium, 2 - 12 µg/ml (r = 0.9995) for atenolol and 2 - 14 µg/ml (r = 0.9993) for hydrochlorothiazide. The results of the method were validated statistically and by recovery studies.

Keywords: Atenolol, hydrochlorothiazide, losartan potassium, spectrophotometric method

Losartan potassium (LOK) is an angiotensin II receptor antagonist and chemically it is 2-n-butyl-4-chloro-5-hydroxymethyl-1-[2’-(1H-tetrazol-5-yl)(biphenyl-4-yl)methyl]imidazole, a strong antihypertensive agent.[1] Atenolol (ATL) is a cardioselective β-blocker and chemically it is (RS)-4-(2 hydroxy-3-isopropylaminopropoxy)-phenylacetamide.[2,3] Hydrochlorothiazide (HCTZ) is chemically 6-chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide1, 1-dioxide. Literature survey revealed that visible spectrophotometric,[4,5] HPLC[6] and some spectrophotometric,[7,8] HPLC[9] methods are available for the estimation of LOK and ATL from pharmaceutical formulations respectively. Also, different methods are available for the estimation of HCTZ.[1013] So it was thought to develop an analytical method for the determination of all three drugs in their combined dosage form.

In the present investigation, an attempt has been made to develop a simple and economical spectrophotometric method with greater precision, accuracy and sensitivity for the analysis of atenolol, losartan potassium and hydrochlorothiazide in bulk and dosage forms.

Experimental

Instrumentation

The present work was carried out on Schimadzu UV-2450 series spectrophotometer having double beam detector configuration. The absorption spectra of reference and test solutions were carried out in 1 cm quartz cell over the range of 200 - 400 nm.

Solvents

Methanol (AR Grade, S.D. Fine chemicals, Mumbai, India) and distilled water.

Procedure: Employing simultaneous equations (Shimadzu 2450)

Standard stock solutions of LOK, ATL and HCTZ were prepared separately by dissolving 10 mg of each drug in 20 ml methanol and diluted to 100 ml with distilled water. From the overlain spectra (shown in Figure 1) of LOK (20µg/ ml) and ATL (20 µg/ml), two wavelengths 251.60 nm of LOK and 224.20 nm of ATL were selected. The overlain spectra (shown in Figure 2) for ATL (8µg/ ml) and HCTZ (2µg/ ml), two wavelength 224.20 nm and 271.60 nm, were selected respectively. The linearity was found to be in the range of 5 - 35 µg/ml, 2 - 12 µg/ml and 2-14µg/ ml for LOK, ATL and HCTZ, respectively. The optical characteristics and statistical data of regression equation are shown in Table 1.

Figure 1
Overlain spectra of LOK and ATL in methanol water
Figure 2
Overlain spectra of ATL and HCTZ in methanol water
Table 1
Optical characteristics and statistical data of the regression equation

The method is based on simultaneous equation[11] and utilizes corresponding absorbance maximas, i.e. 251.60 nm of LOK, 224.20 nm of ATL and 271.60 nm for quantification. The mean absorptivity coefficients of both drugs at each wavelength were determined from different dilutions (six independent determinations) of corresponding drugs within Beer’s law concentration range limit. Using these, a set of two simultaneous equations were framed for two combinations:

Simultaneous equation for LOK and ATL

A251.60=C320.25LOK+8.1CATL...
(1)
A224.20=661.75CLOK+384.50CATL
(2)

where, CLOK and CATL are the concentrations in g /100ml in sample solution.

By rearranging equations 1 and 2, concentration CLOK and CATL can be obtained as,

CLOK=A2×8.1-A1×380.50/-116494.95
(3)
CATL=A1×661.75-A2×320.25/-116494.95
(4)

Simultaneous equation for ATL and HCTZ

A224.20=C866.75LOK+1288CATL
(5)
A271.60=106.0CLOK+720CATL
(6)

where CATL and CHCZT are the concentrations in g /100 ml in sample solution.

By rearranging equations 1 and 2, concentration CLOK and CATL can be obtained as,

CATL=A2×1288-A1×720/-487532
(7)
CHCZT=A1×106.0-A2×866.75/-487532
(8)

Preparation and analysis of tablet formulations

Commercial tablets procured from local market were used for analysis. Twenty tablets (Revas AT) were weighed and crushed to obtain a fine powder. An accurately weighed, sample equivalent to 50 mg of LOK was taken in a stoppered volumetric flask (100.0 ml); 20ml of methanol was added and sonicated for 10 min. The solution was filtered through Whatmann filter paper (No. 41) and volume was made up to the mark with distilled water. After appropriate dilutions, the absorbances of the sample solutions were recorded at 251.60 nm and 224.20 nm i.e.A251.60 and A224.20 equations 3 and 4. Also, the same procedure is repeated for ATEN-H. After appropriate dilutions, the absorbances of the sample solutions were recorded at 224.20 nm and 271.60 nm i.e.A224.20 and A271.60 equations 5 and 6. The analysis procedure was repeated five times, with tablet formulations of two brands. The results of analysis of tablet formulations are presented in Table 2.

Table 2
Results of analysis of pharmaceutical formulations

Recovery studies

The recovery studies were carried out by adding a known amount of standard solution of LOK and ATL to preanalyzed tablet solutions. The recovery studies were carried at 80%, 100% and 120% level. The results of recovery studies are shown in Tables Tables33 and and44.

Table 3
Results of recovery studies of ATL and LOK
Table 4
Results of recovery studies of ATL and HCTZ

Results and Discussion

The proposed method for the determination of atenolol, linear regression of absorbance on concentration gave the equation Y= 0.01713X + 0.08503 with a correlation coefficient (r) of 0.9995; for losartan potassium, linear regression of absorbance on concentration gave the equation Y= 0.02127X + 0.03315 with a correlation coefficient (r) of 0.9991; and for hydrochlorothiazide, linear regression of absorbance on concentration gave the equation Y= 0.00657X + 0.06673 with a correlation coefficient (r) of 0.9993. Recovery studies were carried out at three different levels, by adding 80%, 100% and 120 % of pure drug solution to different samples of tablet powder solution. From the amount of drug found, percentage recovery was calculated. Precision was calculated as repeatability (% RSD) and inter and intra day variation (% RSD) for both the drugs. The repeatability and ruggedness data are presented in Table 5. Both the methods were successfully used to estimate the amount of ATL in combination with LOK and HCTZ present in the marketed formulation.

Table 5
Repeatability and ruggedness data

Conclusion

Atenolol exhibited maximum absorption at 224 nm and obeyed Beer’s law in the concentration range of 2-12 µg / ml; losartan potassium exhibited maximum absorption at 251 nm and obeyed Beer’s law in the concentration range of 5-30 µg / ml; and hydrochlorthiazide exhibited maximum absorption at 271 nm and obeyed Beer’s law in the concentration range of 2-14 µg / ml. The percentage recovery value for atenolol was 99.46% to 100.58%; for losartan potassium was 100.3% to 101.2 %; and for hydrochlorthiazide was 99.93% to 100.67%. This indicates that there is no interference of the excipients present in the formulations. The developed method was found to be accurate, precise, repeatable and reproducible and can be used for the routine analysis of atenolol, losartan potassium and hydrochlorthiazide in bulk drug and formulations.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

References

1. Indian Pharmacopoeia. Government of India. Delhi: Ministry of Health and FamilyWelfare; 1996. p. 72.
2. HMSO. Vol. 1. Cambridge: International edn; 2004. British Pharmacopoeia; p. 179.
3. Lastra OC, Lemus IG, Sanchez HJ, Perez RF. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. J Pharm Biomed Anal. 2003;33:175–80. [PubMed]
4. Shankar MB, Metha FA, Bhatt KK, Metha RS, Geetha M. Spectrophotometric determination of losarton potassium and hydrochlorthiazide in tablet. J Pharm Sci. 2003:167–70.
5. Erk N. Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique. J Pharm Biomed Anal. 2001:24,603–11. [PubMed]
6. Prasad CV, Parihar C, Sunil K, Parimoo P. Simultaneous determination of amiloride HCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy. J Pharm Biomed Anal. 1998;17:877–84. [PubMed]
7. Al-Ghannam SM. A simple spectrophotometric method for the determination of beta-blockers in dosage forms. J Pharm Biomed Anal. 2006;40:151–6. [PubMed]
8. Lamprecht G, Kraushofer T, Stoschitzky K, Lindner W. Enantioselective analysis of (R)- and (S)-atenolol in urine samples by a high-performance liquid chromatography column-switching setup. J Chromatogr B Biomed Sci Appl. 2000;740:219–26. [PubMed]
9. Huang T, He Z, Yang B, Shao L, Zheng X, Duan G. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution. J Pharm Biomed Anal. 2006;41:644–8. [PubMed]
10. Abdel Razak O. Electrochemical study of hydrochlorothiazide and its determination in urine and tablets. J Pharm Biomed Anal. 2004;34:433–40. [PubMed]
11. Lusina M, Cindrić T, Tomaić J, Peko M, Pozaić L, Musulin N. Stability study of losartan/hydrochlorothiazide tablets. Int J Pharm. 2005;291:127–37. [PubMed]
12. Ertürk S, Cetin SM, Atmaca S. Simultaneous determination of moexipril hydrochloride and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods. J Pharm Biomed Anal. 2003;33:505–11. [PubMed]
13. Beckett AH, Stenlake JB. Part 2. 4th ed. New Delhi: CBS publisher; 1997. Practice pharmaceutical chemistry.

Articles from Journal of Pharmacy & Bioallied Sciences are provided here courtesy of Medknow Publications